Holen Sie sich die Stockscreener-App
15.52
3.33%
0.50
Handel nachbörslich:
16.29
0.77
+4.96%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TVTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$15.02
Offen:
$15.2
24-Stunden-Volumen:
1.56M
Relative Volume:
0.91
Marktkapitalisierung:
$1.38B
Einnahmen:
$203.45M
Nettoeinkommen (Verlust:
$-351.45M
KGV:
-3.411
EPS:
-4.55
Netto-Cashflow:
$-369.41M
1W Leistung:
-2.02%
1M Leistung:
-26.62%
6M Leistung:
-20.69%
1J Leistung:
+109.16%
1-Tages-Spanne:
$14.84
$15.52
1-Wochen-Bereich:
$14.75
$16.30
52-Wochen-Spanne:
$6.80
$25.29
Travere Therapeutics Inc Stock (TVTX) Company Profile
Firmenname
Travere Therapeutics Inc
Sektor
Branche
Telefon
888-969-7879
Adresse
3611 VALLEY CENTRE DR, SAN DIEGO
Vergleichen Sie TVTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
15.52 | 1.36B | 203.45M | -351.45M | -369.41M | -4.55 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-21 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-09 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-03-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-12-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-11-20 | Eingeleitet | Citigroup | Neutral |
| 2023-09-22 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-07-21 | Eingeleitet | JP Morgan | Overweight |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Neutral |
| 2023-05-22 | Eingeleitet | TD Cowen | Outperform |
| 2023-05-05 | Hochstufung | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-21 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Hold |
| 2022-12-05 | Eingeleitet | Wells Fargo | Overweight |
| 2022-09-21 | Eingeleitet | Bryan Garnier | Sell |
| 2022-07-14 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-02-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-26 | Herabstufung | Wedbush | Outperform → Neutral |
Alle ansehen
Travere Therapeutics Inc Aktie (TVTX) Neueste Nachrichten
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.TVTX - PR Newswire
Levi & Korsinsky Launches Fraud Investigation on Behalf of Travere Therapeutics, Inc. (TVTX) Shareholders - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Travere Therapeutics, Inc. (TVTX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Would Travere Therapeutics (NASDAQ:TVTX) Be Better Off With Less Debt? - simplywall.st
Lost Money on Travere Therapeutics, Inc. (TVTX)? Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire
Travere Therapeutics, Inc. (TVTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Investors to Connect - ACCESS Newswire
FILSPARI to Transform Kidney Disease Care with Its Revolutionary Treatment Approach | DelveInsight - The Malaysian Reserve
Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Purchased by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Cystinuria Pipeline 2025: Groundbreaking Clinical - openPR.com
Where are the Opportunities in (TVTX) - news.stocktradersdaily.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Travere Therapeutics, Inc. (TVTX) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Ameriprise Financial Inc. Purchases 162,649 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
2025-05-23 | Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Investors to Inquire about Securities Investigation | NDAQ:TVTX | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Stockholders to Connect - ACCESS Newswire
2025-05-20 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Stockholders to Connect | NDAQ:TVTX | Press Release - Stockhouse
Travere Therapeutics: Establishing A Position After Last Week's Selloff (NASDAQ:TVTX) - Seeking Alpha
Travere Therapeutics’ SWOT analysis: stock outlook amid regulatory review By Investing.com - Investing.com Nigeria
Travere Therapeutics’ SWOT analysis: stock outlook amid regulatory review - Investing.com
Travere Therapeutics (NASDAQ:TVTX) Shares Gap Down – Should You Sell? - Defense World
Travere Therapeutics (NASDAQ:TVTX) Earns Outperform Rating from Wedbush - Defense World
The Manufacturers Life Insurance Company Reduces Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
Stifel maintains hold on Travere stock amid FDA review delay By Investing.com - Investing.com South Africa
Travere Therapeutics Holds Annual Meeting, Elects Directors - TipRanks
The Plot Twist That Caused IBD 50's 10th Seed To Plummet - Investor's Business Daily
Travere Therapeutics stock falls on FDA review setback By Investing.com - Investing.com Canada
Travere Therapeutics (TVTX) Receives Outperform Rating from Wedb - GuruFocus
Travere Therapeutics (TVTX) Moves Forward with FILSPARI FDA Review | TVTX Stock News - GuruFocus
Travere Therapeutics (TVTX) Receives Outperform Rating from Wedbush | TVTX Stock News - GuruFocus
Travere flops as FDA accepts Filspari sNDA but plans AdCom - The Pharma Letter
Travere Therapeutics (TVTX) Receives a Buy from Bank of America Securities - The Globe and Mail
IBD 50 Stock Travere Therapeutics Nosedived On An FDA Decision — Here's Why - inkl
Travere Therapeutics' FDA Application Accepted for Filspari in Rare Kidney Disease - marketscreener.com
Cantor Fitzgerald maintains overweight on Travere Therapeutics stock - Investing.com
Travere (TVTX) Shares Drop as FDA Declines Priority Review | TVT - GuruFocus
Travere Therapeutics (TVTX) Sees Buying Opportunity Amid Review Timeline News | TVTX Stock News - GuruFocus
Northern Trust Corp Has $13.14 Million Position in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
Travere Stock Nosedives As FDA Schedules Advisory Meeting For Kidney Drug's Supplemental Use: Retail Shrugs Off Worries - NewsBreak: Local News & Alerts
Travere Therapeutics’ sNDA for FILSPARI accepted by FDA - Investing.com Nigeria
Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS - BioSpace
Travere stock falls on FDA AdCom for Filspari approval (TVTX) - Seeking Alpha
Travere Therapeutics (TVTX) Moves Forward with FILSPARI FDA Revi - GuruFocus
Travere Therapeutics’ FDA Acceptance for FILSPARI Application - TipRanks
Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS | TVTX Stock News - GuruFocus
(TVTX) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Transcript : Travere Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 03 - marketscreener.com
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | TVTX Stock News - GuruFocus
IgA Nephropathy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences, Shanghai Alebund Pharmaceuticals - The Globe and Mail
Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock Position Reduced by Price T Rowe Associates Inc. MD - Defense World
Finanzdaten der Travere Therapeutics Inc-Aktie (TVTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Travere Therapeutics Inc-Aktie (TVTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Dube Eric M | CHIEF EXECUTIVE OFFICER |
May 05 '25 |
Sale |
21.05 |
18,924 |
398,350 |
419,173 |
| Heerma Peter | CHIEF COMMERCIAL OFFICER |
May 05 '25 |
Sale |
21.05 |
1,771 |
37,280 |
128,215 |
| ROTE WILLIAM E. | Chief Research Officer |
May 05 '25 |
Sale |
21.05 |
3,198 |
67,318 |
100,241 |
| REED ELIZABETH E | Chief Legal Officer and GC |
May 05 '25 |
Sale |
21.05 |
4,920 |
103,566 |
89,482 |
6.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):